Brands: Alyacen 1/35 · Alyacen 7/7/7 · Aranelle · Briellyn +9
Average across 13 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Aurobindo Pharma Limited | generic | 6 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 5 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | generic | 3 | SUPPLYING |
| A-S Medication Solutions | repackager | 3 | SUPPLYING |
| Glenmark Pharmaceuticals Inc., USA | generic | 3 | SUPPLYING |
| Proficient Rx LP | repackager | 2 | SUPPLYING |
| Naari Pte. Limited | unknown | 1 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — USA Nationwide.
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets. — Recalling firm: Teva Pharmaceuticals USA, Inc — nationwide
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets. — Recalling firm: Teva Pharmaceuticals USA, Inc — nationwide
CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing — Recalling firm: Teva Pharmaceuticals USA, Inc. — Nationwide distribution. No foreign or government accounts.
